Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

81. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis

The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

82. Systematic review: self-management support interventions for irritable bowel syndrome

Systematic review: self-management support interventions for irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

83. [Burden of irritable bowel syndrome in Korea]

of medical costs was the highest at 60.0%, followed by transportation costs at 15.4% and productivity loss costs at 24.8%. If other medical costs incurred by patients, such as over-the-counter drug costs and health food costs, are added to the aforementioned costs, the total amount is estimated to be 773.8 billion won. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cost of Illness; Humans; Irritable Bowel Syndrome; Korea Language Published Korean Country of organisation South (...) [Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] [Burden of irritable bowel syndrome in Korea] Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park HJ, Lee PL, Lee JS, Lee KJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Choi MG, Jung HK, Jang BH, Kim Y, Nam MH, Park SY, Park J, Park

2010 Health Technology Assessment (HTA) Database.

84. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study (Abstract)

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS).To assesses the effect of mesalazine (mesalamine) on mucosal immune cells in patients with IBS, through a pilot study.A randomized, double-blind, placebo-controlled trial in 20 patients with IBS in tertiary care setting. Patients were randomized to receive placebo (...) ). Mesalazine significantly increased general well-being (P = 0.038), but had no significant effects on abdominal pain (P = 0.084), bloating (P = 0.177) or bowel habits. No serious drug-related adverse events were reported during the study.Mesalazine is an effective and safe approach to reduce mast cell infiltration and may improve general well-being in patients with IBS. These results support the hypothesis that immune mechanisms represent potential therapeutic targets in IBS.

2009 EvidenceUpdates Controlled trial quality: predicted high

85. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (Abstract)

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. It is unclear whether the diagnosis includes children with different aetiologies for their pain. For the majority no organic cause for their pain can be found on physical examination or investigation. Although most children are likely managed (...) by reassurance and simple measures, a large range of interventions have been recommended.To determine the effectiveness of dietary interventions for recurrent abdominal pain in school-age children.The Cochrane Library (CENTRAL) 2006 (Issue 4), MEDLINE (1966 to Dec 2006), EMBASE (1980 to Dec 2006), CINAHL (1982 to Dec 2007), ERIC (1966 to Dec 2006), PsycINFO (1872 to Dec 2006), LILACS (1982 to Dec 2006), SIGLE (1980 to March 2005), and JICST (1985 to 06/2000) were searched . Where appropriate, search filters

2009 Cochrane

86. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. Full Text available with Trip Pro

was adequate symptom relief during at least two weeks in the previous month, analysed after one, two, and three months of treatment to assess both short term and sustained effectiveness. Secondary end points included irritable bowel syndrome symptom severity score, severity of abdominal pain, and irritable bowel syndrome quality of life scale.The proportion of responders was significantly greater in the psyllium group than in the placebo group during the first month (57% v 35%; relative risk 1.60, 95 (...) Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. To determine the effectiveness of increasing the dietary content of soluble fibre (psyllium) or insoluble fibre (bran) in patients with irritable bowel syndrome.Randomised controlled trial.General practice.275 patients aged 18-65 years with irritable bowel syndrome.12 weeks of treatment with 10 g psyllium (n=85), 10 g bran (n=97), or 10 g placebo (rice flour) (n=93).The primary end point

2009 BMJ Controlled trial quality: predicted high

87. Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome

Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndrome Review: antidepressants and psychological therapies improve symptoms of irritable bowel syndromeCommentary | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) improve symptoms of irritable bowel syndrome Commentary Statistics from Altmetric.com QUESTION In patients with irritable bowel syndrome (IBS), do antidepressant medications or psychological therapies improve symptoms? REVIEW SCOPE Included studies compared antidepressants with placebo or psychological therapies with no treatment or usual care in adults (⩾16 y of age) with IBS diagnosed by established criteria or by a clinician’s opinion. Outcomes were persistent IBS symptoms and adverse events

2009 Evidence-Based Medicine

88. Psychological treatments may be effective for managing irritable bowel syndrome

Psychological treatments may be effective for managing irritable bowel syndrome PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Psychological treatments may be effective for managing irritable bowel syndrome Clinical question How effective are psychological interventions for the treatment of irritable bowel syndrome (IBS)? Bottom line Psychological interventions (cognitive behavioural therapy (...) of irritable bowel syndrome. Cochrane Reviews 2009, Issue 1. Article No: CD006442. DOI: 10.1002/14651858.CD006442.pub2. This review contains 25 studies involving 1858 participants. PEARLS 156, April 2009, written by Brian R McAvoy [References] 1. Drossman DA et al. Gastroenterology 1997;112:2120-2137 are funded by the New Zealand Guidelines Group. PEARLS provide guidance on whether a treatment is effective or ineffective. PEARLS are prepared as an educational resource and do not replace clinician judgement

2009 Publication 410

89. Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome

and specificity for diagnosing irritable bowel syndrome Statistics from Altmetric.com QUESTION What is the accuracy of individual symptoms and combinations of clinical findings for diagnosing irritable bowel syndrome (IBS)? REVIEW SCOPE Included studies compared individual symptoms or combinations of clinical findings with investigational tests (colonoscopy, barium enema, or computed tomographic colography) for diagnosing IBS in unselected patients >16 years of age who had lower gastrointestinal (GI) symptoms (...) Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome Review: clinical findings had moderate sensitivity and specificity for diagnosing irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password

2009 Evidence-Based Medicine

90. Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome

Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: fibre, antispasmodics, and peppermint oil are all effective for irritable bowel syndrome Article Text Therapeutics Review: fibre, antispasmodics, and peppermint oil are all effective

2009 Evidence-Based Medicine

91. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

92. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis

anticholinergic effects for elderly patients or C-IBS and imipramine or amitriptyline for D-IBS and patients with insomnia. Research : The authors stated that additional large RCTs with strict surveillance on compliance were needed to further explain the role of antidepressants for management of IBS in routine practice. Funding National Science Foundation, Tehran. Bibliographic details Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis (...) Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Efficacy of tricyclic antidepressants in irritable bowel syndrome: a meta-analysis Rahimi R, Nikfar S, Rezaie A, Abdollahi M CRD summary This review concluded that low-dose tricyclic antidepressants (TCAs) exhibited clinically and statistically significant control of irritable bowel syndrome (IBS) symptoms. Caution is warranted

2009 DARE.

93. Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome

Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

94. Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care

Systematic review: accuracy of symptom-based criteria for diagnosis of irritable bowel syndrome in primary care Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 DARE.

95. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome (Abstract)

Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome The intestinal permeability is increased in patients with diarrhoea-predominant irritable bowel syndrome (D-IBS).To determine the possible efficacy of lactic acid bacteria on the increased intestinal permeability in D-IBS.Treatment was employed for 4 weeks in a randomized single blind placebo controlled study with 30 D-IBS patients. Patients were (...) given either probiotic fermented milk (Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus and Bifidobacterium Longum) or milk beverage containing no bacteria. The clinical symptoms were scored and intestinal permeability was measured by a triple sugar test before and after treatment.Small bowel permeability was measured as the ratio of lactulose and mannitol recovery and colonic permeability was measured as the total mass of sucralose excretion (mg). After probiotics

2008 EvidenceUpdates Controlled trial quality: uncertain

96. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome (Abstract)

Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome In models of irritable bowel syndrome (IBS), asimadoline, a kappa-opioid agonist, improves pain and abnormal bowel function.To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double-blind, randomized, placebo-controlled trial.Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure

2008 EvidenceUpdates Controlled trial quality: predicted high

97. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents (Abstract)

Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents To determine the efficacy of amitriptyline (AMI) in treating irritable bowel syndrome (IBS) in adolescents.Adolescents 12 to 18 years with newly diagnosed IBS were surveyed with a symptom checklist, pain rating scale, visual analog scale, and IBS quality of life (QOL) questionnaire. Subjects were randomized in a double-blinded fashion to receive AMI or placebo, and again completed (...) , .039, and .004).AMI significantly improves overall QOL in adolescents with IBS and should be a therapeutic option for adolescents with this disorder.

2008 EvidenceUpdates Controlled trial quality: predicted high

98. Effectiveness of probiotics in the treatment of irritable bowel syndrome Full Text available with Trip Pro

Effectiveness of probiotics in the treatment of irritable bowel syndrome Recently, the use of tegaserod and alosetron -- drugs approved for the treatment of irritable bowel syndrome (IBS) -- has been restricted because of adverse events. This has resulted in a need for additional modalities for the treatment of IBS. Our objective was to determine the effectiveness of probiotics in the global relief of symptoms associated with IBS and in the improvement of flatulence, abdominal pain, transit (...) time, and bacterial counts. Using the MEDLINE database from 1966-October 2007 and manually searching article references for relevant articles and abstracts, we identified 14 blinded, placebo-controlled clinical trials of the effectiveness of probiotics in the treatment of IBS. Of 11 studies in which overall symptom relief was assessed, seven indicated a significant improvement with probiotics versus placebo. Five of eight investigations of abdominal pain and distention revealed a benefit

2008 EvidenceUpdates

99. Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. (Abstract)

Psychosocial interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Between 4% and 25% of school-age children complain of recurrent abdominal pain (RAP) of sufficient severity to interfere with daily activities. For the majority of such children, no organic cause for their pain can be found on physical examination or investigation. Although most children are managed by reassurance and simple measures, a large range of psychosocial interventions (...) filters.Any study in which the majority of participants were school-age children fulfilling standard criteria for RAP (Apley or the Rome II criteria for functional gastrointestinal diseases) , randomly allocated to any psychosocial treatment compared to standard care or waiting list, were selected.References identified by the searches were independently screened against the inclusion criteria by two reviewers. Data were extracted and analysed using RevMan 4.2.10.Six randomised trials (including a total

2008 Cochrane

100. Irritable bowel syndrome in adults: diagnosis and management

and evidence used to update these recommendations. Irritable bowel syndrome (IBS) is a chronic, relapsing and often life-long disorder. It is characterised by the presence of abdominal pain or discomfort, which may be associated with defaecation and/or accompanied by a change in bowel habit. Symptoms may include disordered defaecation (constipation or diarrhoea or both) and abdominal distension, usually referred to as bloating. Symptoms sometimes overlap with other gastrointestinal disorders such as non (...) Initial assessment Initial assessment 1.1.1.1 Healthcare professionals should consider assessment for IBS if the person reports having had any of the following symptoms for at least 6 months: A Abdominal pain or discomfort B Bloating C Change in bowel habit. [2008] [2008] Irritable bowel syndrome in adults: diagnosis and management (CG61) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 10 of 221.1.1.2 All people

2008 National Institute for Health and Clinical Excellence - Clinical Guidelines